HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch

Lilly’s tirzepatide sheds lean muscle harder than Novo’s semaglutide, study suggests

While Eli Lilly’s tirzepatide helps patients drop more weight than Novo Nordisk’s semaglutide, this might come with greater loss in lean body mass, according to a new study awaiting peer review. The analysis, shared as ...

By Endpoints News · Apr 17, 2026 · via Endpoints News
Lilly’s tirzepatide sheds lean muscle harder than Novo’s semaglutide, study suggests

Image: Endpoints News

This is an aggregated industry headline. Read the full story at Endpoints News

Tags
theweekformat:headlineheadlineEndpoints News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
Rising Stars: WPP's Meghan O'Hora on the 'complex puzzle' of oncology drug marketing
The WeekFiercePharma ↗
For Meghan O'Hora, pharma marketing isn't about patients. It's about people and making real connections that h…
Jun 3, 2026
New heights for NewLimit as anti-aging biotech nabs $435M to rejuvenate old cells
The WeekFierceBiotech ↗
Anti-aging startup NewLimit is back with a fresh fundraise of $435 million after landing on its first clinic-r…
Jun 3, 2026
Cingulate’s FDA Rejection Centers on Manufacturing, Not Safety
The WeekBriefing
The agency’s Complete Response Letter delays CTx‑1301, the biotech’s first commercial hopeful, over CMC issues…
Jun 3, 2026